

A Tumor-targeted Theranostic Nanomedicine with strong absorption in the NIR-II Biowindow for Imaging-Guided Multi-gradient Therapy

Qi Chen,^{a, #}, Ziliang Zheng ^{a, #}, Xiaojing He ^{a, #}, Shuo Rong ^a, Yufei Qin ^a, Xiaoyang Peng ^a, and
Ruiping Zhang^{b, *}

^a Department of biochemistry and molecular biology, Shanxi Medical University, Taiyuan 030001, China

^b Department of Radiology, third hospital of Shanxi Medical University, Taiyuan 030032, China

* Corresponding authors. Email: zrp_7142@sxmu.edu.cn (R. Zhang).

These authors contributed equally to this work.

Supporting Figures




Figure S1. XRD pattern of CuS-PGH NMs.




Figure S2. Digital photos of CuS-PGH NMs (1 mg/mL) in water, PBS, saline and cell medium after 24 h.




Figure S3. Representative TEM image of CuS.




Figure S4. Photograph of the deep-tissue NIR-II PTT experimental samples setup.




Figure S5. Intracellular ROS detection after 4T1 cells treatment with the samples. The scar bar was 100 μm .




Figure S6. Tumor growth curves of mice from different groups after various treatments.




Figure S7. H&E staining of major organ tissues collected from mice at the end of treatment. Scale bar is 200 μm .